A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection

BACKGROUND: Coronavirus disease 2019 (COVID-19) is an immunoinflammatory and hypercoagulable state that contributes to respiratory distress, multi-organ dysfunction, and mortality. Dipyridamole, by increasing extracellular adenosine, has been postulated to be protective for COVID-19 patients through...

Descripción completa

Detalles Bibliográficos
Autores principales: Singla, Amit, Dadario, Nicholas B., Singla, Ashima, Greenberg, Patricia, Yan, Rachel, Nanda, Anil, Boison, Detlev, Malhotra, Rakesh, Patel, Sunil, Nipun, Suri, Maninderpal, Kaur, Castro, Dorothy, Bdiiwi, Sanaa, Boktor, Hala, Kyi, Htay Htay, Sutherland, Anne, Patrawalla, Amee, Ly, Kevin, Xie, Yingda, Sonig, Ashish, Khandelwal, Priyank, Liu, James, Koziol, Joseph, Finkle, Diana, Subanna, Sara, Libutti, Steven K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886260/
https://www.ncbi.nlm.nih.gov/pubmed/36716303
http://dx.doi.org/10.1371/journal.pone.0274243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886260/
https://www.ncbi.nlm.nih.gov/pubmed/36716303
http://dx.doi.org/10.1371/journal.pone.0274243

Ejemplares similares